Get the Daily Brief
Latest Biotech News
Thermo Fisher Beats Q2 Expectations, Raises 2025 Guidance
Thermo Fisher Scientific exceeded Q2 2025 revenue and earnings estimates, driven by strong growth in life sciences solutions and laboratory products segments. The company increased full-year...
AstraZeneca’s Gefurulimab Clears Phase 3 in Myasthenia Gravis
AstraZeneca reported positive Phase 3 PREVAIL trial outcomes for gefurulimab, a self-administered C5 complement inhibitor for anti-acetylcholine receptor antibody-positive generalized myasthenia...
New Genetic Strategy Halts Malaria Transmission in Mosquitoes
A Nature-published study describes a CRISPR-Cas9 editing approach that changes a single amino acid in the FREP1 gene of Anopheles mosquitoes, rendering them unable to transmit malaria without...
FDA Launches National Priority Voucher for Accelerated Review
The FDA initiated the Commissioner’s National Priority Voucher (CNPV) pilot program to expedite drug review times to 1–2 months for therapies addressing designated U.S. health priorities,...
Dispatch Bio Unveils $216M Solid Tumor Immunotherapy Approach
Dispatch Bio launched with $216 million in funding and a novel immunotherapy platform aiming to target a broad range of solid tumors. The company’s technology uses a viral vector to deliver a...
Abivax’s Ulcerative Colitis Drug Soars After Phase 3 Wins
Abivax’s orally administered miRNA-124 enhancer, obefazimod, demonstrated significant clinical remission and response rates across large Phase 3 studies in moderately to severely active ulcerative...
FDA Extends Review on GSK’s Myeloma Drug Blenrep
The FDA has delayed its review deadline for GSK’s multiple myeloma drug Blenrep to October 23 to further evaluate additional data submitted by the company. This follows a negative advisory...
AI Advances Protein Design for Cancer Immunotherapy
Researchers led by Nobel Laureate David Baker have developed AI-driven design of highly specific protein binders that mimic T cell receptors targeting peptide-MHC complexes on diseased cells....
1000 Genomes Project Enriched by Long-Read Sequencing Collaborations
The 1000 Genomes Project Long-Read Sequencing Consortium expanded its scope by integrating PacBio data alongside Oxford Nanopore sequencing, aiming to sequence the entire 1000 Genomes cohort with...
Sarepta Therapeutics Faces FDA Demands Amid Gene Therapy Crisis
Sarepta Therapeutics is under intense regulatory scrutiny as the FDA halted shipments of its Duchenne muscular dystrophy gene therapy Elevidys in several countries and called for new studies to...
Thermo Fisher Beats Q2 Estimates, Raises 2025 Guidance
Thermo Fisher Scientific reported better-than-expected Q2 revenue and earnings, with a 3% sales increase year-over-year to $10.86 billion. Life sciences solutions and laboratory products segments...
Malaria Blocked by CRISPR-Edited Mosquito Gene Variant
Scientists have engineered a CRISPR-Cas9 gene editing system that modifies a single amino acid in the mosquito FREP1 gene, rendering mosquitoes unable to transmit malaria parasites. Unlike...
LEO Pharma’s Anzupgo Gains FDA Approval for Chronic Hand Eczema
LEO Pharma’s topical JAK inhibitor cream Anzupgo (delgocitinib) became the first FDA-approved therapy specifically for chronic hand eczema in the U.S. Indicated for moderate to severe cases not...
FDA Launches Fast Track Program for U.S. Drug Onshoring and Affordability
The FDA opened applications for its Commissioner’s National Priority Voucher pilot program offering expedited review timelines of 1-2 months for medicines addressing key U.S. priorities....
AI-Driven Protein Design Enhances Cancer Immunotherapy
Researchers led by Nobel Laureate David Baker have leveraged artificial intelligence to design highly specific protein binders targeting peptides presented by major histocompatibility complex...
1000 Genomes Project Expands Long-Read Sequencing Data with Multiplatform Consortium
The 1000 Genomes Project Long-Read Sequencing Consortium, led by University of Washington researchers, has expanded its dataset by adding Pacific Biosciences (PacBio) long-read sequencing...
Dispatch Bio Launches with $216M for Universal Solid Tumor Immunotherapy
Dispatch Bio has officially launched with $216 million in funding, backing an immunotherapy platform designed to treat diverse solid tumors. The company’s approach involves delivering a viral...
Sarepta Therapeutics Faces Covid Safety and Market Challenges With Duchenne Gene Therapy
Sarepta Therapeutics is grappling with regulatory and safety issues surrounding Elevidys, its gene therapy for Duchenne muscular dystrophy (DMD). The FDA requested a market withdrawal due to...
Abivax’s Ulcerative Colitis Drug Delivers Positive Phase 3 Data, Stock Surges
French biotech Abivax reported positive results from two Phase 3 trials of obefazimod, an oral microRNA-124 enhancer for moderately to severely active ulcerative colitis patients. The 50 mg dose...
Roche’s Diagnostics Division Faces China Pricing Reforms, Reports Flat Revenues
Roche Diagnostics reported a 3% revenue decline in the first half of 2025, mainly driven by volume-based procurement and healthcare pricing reforms in China, which caused a 26% sales drop there....